ArticleNeuropharmacology2019
The highly selective dopamine D
Open access · greenAbstract read
In one paragraph
Article in Neuropharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
6.4field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 83 citations in OpenAlex.
- Pramipexole in addition to mood stabilisers for treatment-resistant bipolar depression: the PAX-BD randomised double-blind placebo-controlled trial.Health technology assessment (Winchester, England) · 2025Trial
- A randomised double-blind, placebo-controlled trial of pramipexole in addition to mood stabilisers for patients with treatment-resistant bipolar depression (the PAX-BD study).Journal of psychopharmacology (Oxford, England) · 2025Trial
- Can the incentive-sensitization theory of addiction incorporate addiction to opioid drugs?Psychopharmacology · 2026Review
- Effects of acute adolescent stress on the acquisition and maintenance of intravenous oxycodone self-administration in male and female rats.Drug and alcohol dependence · 2026Article
- Effects of acute adolescent stress on the acquisition and maintenance of intravenous oxycodone self-administration in male and female rats.bioRxiv : the preprint server for biology · 2025Article
- Discovery, Characterization, and Optimization of a Novel Positive Allosteric Modulator-Antagonist of the DJournal of medicinal chemistry · 2025Article
- Selective dopamine D3 receptor partial agonist (±)VK4-40 reduces the reinforcing strength of d-amphetamine but not cocaine in rhesus monkeys responding under a progressive-ratio schedule of reinforcement.Drug and alcohol dependence · 2024Article
- AM6527, a neutral CB1 receptor antagonist, suppresses opioid taking and seeking, as well as cocaine seeking in rodents without aversive effects.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024Article
- The selective DNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024Article
- In Vitro and In Vivo Pharmacological Profiles of LENART01, a Dermorphin-Ranatensin Hybrid Peptide.International journal of molecular sciences · 2024Article
- Optical Intracranial Self-Stimulation (oICSS): A New Behavioral Model for Studying Drug Reward and Aversion in Rodents.International journal of molecular sciences · 2024Review
- GPR55 is expressed in glutamate neurons and functionally modulates drug taking and seeking in rats and mice.Translational psychiatry · 2024Article
- The dopamine 3 receptor as a candidate biomarker and therapeutic for opioid use disorder.Addiction biology · 2024Article
- Effects of selective dopamine D3 receptor partial agonist/antagonists on oxycodone self-administration and antinociception in monkeys.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2023Article
- PPARα and PPARγ are expressed in midbrain dopamine neurons and modulate dopamine- and cannabinoid-mediated behavior in mice.Molecular psychiatry · 2023Article
- Pharmacological and Physicochemical Properties Optimization for Dual-Target Dopamine DJournal of medicinal chemistry · 2023Article
- PPARα and PPARγ are expressed in midbrain dopamine neurons and modulate dopamine- and cannabinoid-mediated behavior in mice.Research square · 2023Article
- 3,4-Methylenedioxypyrovalerone High-Responder Phenotype as a Tool to Evaluate Candidate Medications for Stimulant Use Disorder.The Journal of pharmacology and experimental therapeutics · 2023Article
- HIV gp120 impairs nucleus accumbens neuroimmune function and dopamine D3 receptor-mediated inhibition of cocaine seeking in male rats.Addiction neuroscience · 2023Article
- Dopamine DJournal of medicinal chemistry · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 1 country.
Chloe J JordanMolecular Targets and Medications Discovery Branch, National Institute on Drug Abuse, Intramural Research Program, Baltimore, MD, 21224, USA.
Bree HumburgMolecular Targets and Medications Discovery Branch, National Institute on Drug Abuse, Intramural Research Program, Baltimore, MD, 21224, USA.
Myra RiceMolecular Targets and Medications Discovery Branch, National Institute on Drug Abuse, Intramural Research Program, Baltimore, MD, 21224, USA.
Guo-Hua BiMolecular Targets and Medications Discovery Branch, National Institute on Drug Abuse, Intramural Research Program, Baltimore, MD, 21224, USA.
Zhi-Bing YouMolecular Targets and Medications Discovery Branch, National Institute on Drug Abuse, Intramural Research Program, Baltimore, MD, 21224, USA.
Anver Basha ShaikMolecular Targets and Medications Discovery Branch, National Institute on Drug Abuse, Intramural Research Program, Baltimore, MD, 21224, USA.
Jianjing CaoMolecular Targets and Medications Discovery Branch, National Institute on Drug Abuse, Intramural Research Program, Baltimore, MD, 21224, USA.
Alessandro BonifaziMolecular Targets and Medications Discovery Branch, National Institute on Drug Abuse, Intramural Research Program, Baltimore, MD, 21224, USA.
Alexandra GadianoMolecular Targets and Medications Discovery Branch, National Institute on Drug Abuse, Intramural Research Program, Baltimore, MD, 21224, USA; Department of Neurology, Johns Hopkins Drug Discovery, The Johns Hopkins University School of Medicine, 855 N. Wolfe Street, Baltimore, MD, 21205, USA.
Rana RaisDepartment of Neurology, Johns Hopkins Drug Discovery, The Johns Hopkins University School of Medicine, 855 N. Wolfe Street, Baltimore, MD, 21205, USA.
Barbara SlusherDepartment of Neurology, Johns Hopkins Drug Discovery, The Johns Hopkins University School of Medicine, 855 N. Wolfe Street, Baltimore, MD, 21205, USA.
Amy Hauck NewmanMolecular Targets and Medications Discovery Branch, National Institute on Drug Abuse, Intramural Research Program, Baltimore, MD, 21224, USA. Electronic address: amy.newman@nih.gov.
Zheng-Xiong XiMolecular Targets and Medications Discovery Branch, National Institute on Drug Abuse, Intramural Research Program, Baltimore, MD, 21224, USA. Electronic address: zxi@mail.nih.gov.
National Institute on Drug Abuse · USJohns Hopkins University · US
Funding
Novel Dopamine D3 Receptor Ligands ZIADA000424 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI NEWMAN, AMY HAUCK · 2009 to 2025
$25.9MNOVEL DOPAMINE D3 RECEPTOR LIGANDSZ01DA000424 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI NEWMAN, AMY HAUCK · 1999 to 2008
$1.8MIntramural NIH HHS Z01 DA000424Intramural NIH HHS Z99 DA999999
Abstract
Prescription opioid abuse is a global crisis. New treatment strategies for pain and opioid use disorders are urgently required. We evaluated the effects of R-VK4-40, a highly selective dopamine (DA) D
Indexed as
RewardAnalgesics, OpioidAnimalsBehavior, AnimalDopamine AntagonistsDopaminergic NeuronsIndolesMaleNociceptionOptogeneticsOxycodonePiperazinesRatsRats, Long-EvansReceptors, Dopamine D3Reinforcement ScheduleAnalgesics, OpioidDopamine AntagonistsDrd3 protein, ratIndolesOxycodonePiperazinesReceptors, Dopamine D3R-VK4-40Brain-stimulation rewardD(3) receptor antagonistOpioid analgesiaOxycodoneR-VK4-40Self-administration
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.